Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on July 29, 2019, regarding events occurring on July 28, 2019. The filing primarily addresses the appointment of a new Chief Financial Officer and the resignation of the incumbent.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Departure: Yossi Maimon resigned as Vice President and Chief Financial Officer to pursue other opportunities, effective July 22, 2019.
- Executive Appointment: Eyal Rubin was appointed as Senior Vice President and Chief Financial Officer, effective September 22, 2019.
- Transition Plan: Mr. Maimon agreed to assist with the transition of financial and accounting functions until Mr. Rubin's start date.
Guidance, Outlook, and Compensation Details
The filing details the terms of the Employment Agreement between the Company and Mr. Rubin:
- Base Salary: 80,000 New Israeli Shekels per month (approximately $22,680), subject to cost of living adjustments.
- Bonus Structure: An annual discretionary bonus based on objectives set by the Board; a one-time bonus of $400,000 upon a change of control.
- Equity Grant: Options to purchase 800,000 shares of common stock at the closing price on the day preceding the grant. Vesting occurs quarterly over four years, with full acceleration upon a Corporate Transaction or Change in Control.
- Restricted Share Units (RSUs): Potential annual RSUs valued at $100,000, subject to Board approval of a compensation plan by December 31, 2019.
- Termination Terms: The agreement is terminable by the Company with 180 days' written notice and by Mr. Rubin with 90 days' written notice. Termination for cause by the Company requires no notice.
- Benefits: Includes vacation (24 working days), company car, laptop, phone, recreational allowances, and D&O insurance coverage.
Investor Verification Checklist
- Verify the exact closing stock price on the NYSE American for the trading day immediately preceding September 22, 2019, to determine the exercise price of the 800,000 stock options.
- Confirm whether the Board approves the annual compensation plan for RSUs by the December 31, 2019 deadline.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Corporate Transaction" and "Change in Control" regarding option acceleration.
- Monitor subsequent filings for any updates on the Company's liquidity or capital position following the leadership transition.